Shenzhen Bioeasy Biotechnology Co., Ltd.

Equities

300942

CNE100004C78

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
7.06 CNY +1.15% Intraday chart for Shenzhen Bioeasy Biotechnology Co., Ltd. +9.46% -39.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Announces Executive Appointments CI
Certain A Shares of Shenzhen Bioeasy Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Bioeasy Joins Other Biotech Firms in Requesting to Cancel COVID-19 Test Kits MT
Shenzhen Bioeasy Biotechnology Approves Cash Dividend for 2022, Payable on 31 May 2023 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Proposes Final Dividend for 2022 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shenzhen Bioeasy Biotechnology Unit Gets Registration Certificates for Medical Devices MT
Shenzhen Bioeasy Biotechnology Co., Ltd.(XSEC:300942) added to S&P Global BMI Index CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Announces Executive Appointments CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Approves Final Cash Dividend for the Year 2021, Payable on 30 May 2022 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Proposes Final Cash Dividend for the Year 2021 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Certain A Shares of Shenzhen Bioeasy Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 9-FEB-2022. CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Shenzhen Bioeasy Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Shenzhen Xiupu Biological Technology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Bioeasy Biotechnology Co., Ltd. CI
Shenzhen Xiupu Biological Technology Co., Ltd. announced that it expects to receive CNY 100 million in funding from Shenzhen Bioeasy Biotechnology Co., Ltd. CI
Chart Shenzhen Bioeasy Biotechnology Co., Ltd.
More charts
Shenzhen Bioeasy Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production, sales and provision of food safety testing products and related services. The Company’s main products are food safety rapid testing reagents, rapid testing instruments, related testing services and in vitro diagnostic point-of-car testing (POCT) products, such as colloidal gold immunochromatographic test papers, enzyme-linked immunoassay (ELISA) kits, nucleic acids extraction kit, portable food rapid analysis system, infectious disease detection series and fluorescence immunoassay analyzer, etc. Its products are mainly used in dairy, meat, aquatic products, grains and oils, fruits and vegetables and other food fields that require rapid testing, as well as in the cultivation and breeding fields.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 300942 Stock
  4. News Shenzhen Bioeasy Biotechnology Co., Ltd.
  5. Bioeasy Joins Other Biotech Firms in Requesting to Cancel COVID-19 Test Kits